CiRT highlighted at ESMO 2022 presentation

RNS Number : 3485Y

Oxford BioDynamics PLC

06 September 2022

 

Oxford BioDynamics Announces Collaborative Late-Breaking Podium Presentation at the European Society of Medical Oncology (ESMO) 2022 Congress

· The European Society of Medical Oncology (ESMO) 2022 Congress is one of the most prestigious oncology conferences in the world

· Presentation title: "Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)", which included OBD's EpiSwitch® platform technology

· Presenter: Professor Thomas Powles, MBBS, MD, MRCP, Director of Barts Cancer Centre, St. Bartholomew's Hospital

· Timing of presentation: 11:10am CEST, 10 September 2022

· The OBD team will also have an exhibition at booth #419 in Hall 7 (level 7.2) and will be discussing the features of the EpiSwitch® platform and Checkpoint Inhibitor Response Test (CiRT)

Oxford, UK - 6 September, 2022 - Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch® 3D genomics platform, announces its flagship clinical platform will be highlighted in a late-breaking podium presentation at the upcoming European Society of Medical Oncology (ESMO) Annual Congress, which is being held September 9 - 13, 2022, at the Paris Expo Porte de Versailles in Paris, France.

The presentation, titled "Genomic biomarkers in peripheral blood from patients enrolled in the JAVELIN Bladder 100 trial of avelumab first-line maintenance in advanced urothelial carcinoma" will be delivered by renowned oncology specialist Professor Thomas Powles, MBBS, MD, MRCP, Director of Barts Cancer Centre at St. Bartholomew's Hospital. Collaborators from pharma and global medical cancer centers also serve as co-authors on the paper, including Dana-Farber Cancer Institute (MA, USA), Barts Cancer Institute (UK), Fred Hutchinson Cancer Center (WA, USA), Princess Margaret Cancer Center (ON, CA), and Meyer Cancer Center (NY, USA). This late-breaking abstract reflects novel research findings with implications for clinical practice. Further details of the study are under data embargo until September 8th, 2022.

"It is very exciting to have OBD's EpiSwitch® 3D genomics platform utilized in this high profile clinical study with the results being presented in a late-breaking podium at the ESMO Congress next week," said Dr Jon Burrows, OBD's Chief Executive Officer."ESMO is the largest oncology conference in Europe, with almost half of the attendees expected to be US clinicians. This is the ideal audience for our innovative EpiSwitch technology and Checkpoint inhibitor Response Test (CiRT). Through meetings such as this, we are increasing our engagement with practicing medical oncologists, pharma clinical development teams and hospital administrators who are essential for the acceptance and incorporation of the EpiSwitch® platform and CiRT into everyday clinical practice."

OBD's EpiSwitch CiRT is a first-of-its-kind precision medicine test that predicts a cancer patient's likely response to Immune Checkpoint Inhibitors (ICIs), including anti-PD-L1 and anti-PD-1 therapies. Despite their potential efficacy, it is estimated that ICIs are ineffective for up to 70% of patients being treated for cancer. Launched in February 2022, the CiRT blood test has demonstrated best-in-class performance in the prediction of cancer patient response to ICIs, with high sensitivity (93%), specificity (82%), and accuracy (85%) across several ICIs from multiple pharmaceutical companies, in 15 key oncological indications. CiRT is available for immediate clinical utilization both in the UK and the US via the website: myCiRT.com .

The ESMO congress is one of the largest, most prestigious oncology conferences in the world, second only to the American Society of Clinical Oncology (ASCO), which OBD attended earlier in 2022. ESMO is the leading professional organization for medical oncology in Europe and has more than 25,000 members representing oncology professionals worldwide. In 2021, more than 32,700 people attended the ESMO congress from over 155 countries, with 45% of participants consisting of providers from the United States.

Details of the presentation:

Title: "Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)"

Session: Proferred Papers Session 1, GU tumours, non-prostate

Session Time: Saturday, September 10^th, 2022, 10:15 - 11:45am (CEST)

Location:  Paris Expo Porte de Versailles, Brest Auditorium (level 7.1.C)

Please visit http://esmo.mycirt.com to arrange a face-to-face meeting at ESMO. Oxford Biodynamics' clinical and scientific representatives will be available at their Company booth #419 in Hall 7 (level 7.2) on 9 September from 1:30pm-6pm and 10-12 Sept between 10am-6pm CEST.

For further details please contact:

Oxford BioDynamics Plc Jon Burrows, CEO Paul Stockdale, CFO	Tel: [phone]
Shore Capital Nominated Adviser and Broker Stephane Auton John More	Tel: [phone]

Instinctif Partners Melanie Toyne-Sewell Agnes Stephens Katie Duffell	Tel: [phone] [e-mail]
PCG Advisory Group - US Investor Relations Jeff Ramson Kirin Smith	Tel: [phone] [e-mail] [e-mail]

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.

The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial office in Gaithersburg, MD, USA and a reference laboratory in Penang, Malaysia.

For more information, please visit the Company's website, www.oxfordbiodynamics.com, or follow on Twitter or LinkedIn.

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.

In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.

 

END

 

 

NRALAMMTMTTMTTT